Israel

Cognyte to Announce Third Quarter Financial Results on December 21, 2021

Retrieved on: 
Wednesday, December 8, 2021
Software, Technology, Security, Cause of action, Review, Investor relations, Software, Organization, Government, Needle, International, NASDAQ, Solution, Telephone, Risk management

Cognyte Software Ltd. (NASDAQ: CGNT) will conduct a conference call on Tuesday, December 21, 2021 at 8:30am ET to review its third quarter financial results for the period ending October 31, 2021.

Key Points: 
  • Cognyte Software Ltd. (NASDAQ: CGNT) will conduct a conference call on Tuesday, December 21, 2021 at 8:30am ET to review its third quarter financial results for the period ending October 31, 2021.
  • A real-time webcast of the conference call with presentation slides will be available in the Investor Relations section of Cognytes website.
  • The conference call can also be accessed live via telephone at (888) 771-4371 (United States and Canada) and +1 (847) 585-4405 (International).
  • COGNYTE, ACTIONABLE INTELLIGENCE, and ACTIONABLE INTELLIGENCE FOR A SAFER WORLD are trademarks of Cognyte Software or its subsidiaries.

BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant

Retrieved on: 
Wednesday, December 8, 2021
Hemp, Human, CBD, Company, Population, Plant, Fungus, Biotechnology, CSE, Polyphenol, Technology, History, Trichome, Flow Science, Inc., Pain, Agriculture, Fruit, Safety, Social structure, F&B, Radiation, THC, Cannabinoid, Food, Industry, CS, Hazardous waste, Biomass, B2B, Canadian Securities Exchange, Time, CAD, BHSC, Drug, Seaweed, Food preservation

The Cannabis biomass is not genetically modified and was produced using the Company's proprietary BioFarming technology platform, which grows plant cells in their natural structure in proprietary bioreactors.

Key Points: 
  • The Cannabis biomass is not genetically modified and was produced using the Company's proprietary BioFarming technology platform, which grows plant cells in their natural structure in proprietary bioreactors.
  • "With this milestone, we are ready to start engaging with key players in the global Cannabis industry for the right partnerships ahead of the introduction of our new Cannabis products."
  • The biomass consists of Cannabis cells, including Cannabis Trichome cells containing Cannabinoids such as CBD, THC, as well as other compounds that are naturally occurring in the Cannabis plant.
  • Cost: A significant reduction in the production costs, resources, and time required versus indoor and greenhouse Cannabis cultivation.

Similarweb Dials Up Sales Intelligence Solution with Integration of Comprehensive Professional-Contacts Database

Retrieved on: 
Wednesday, December 8, 2021
Technology, Consulting, Marketing, Telecommunications, Communications, Professional Services, Networks, Internet, Data Management, U.S. Securities and Exchange Commission, NYSE, Material, Prospectus, Securities Act of 1933, Postscript, Contact lens, Security (finance), Press, Securities Exchange Act of 1934, Movement, SMS, Intelligence, Sales, Online shopping

Similarweb (NYSE: SMWB), a leading digital intelligence company, today announced that it has enhanced its Sales Intelligence solution with the launch of Contacts, a world-wide database of professional-contacts information.

Key Points: 
  • Similarweb (NYSE: SMWB), a leading digital intelligence company, today announced that it has enhanced its Sales Intelligence solution with the launch of Contacts, a world-wide database of professional-contacts information.
  • The addition of Contacts is the latest in a series of updates to Similarweb Sales Intelligence , and enables sales teams to quickly and easily discover and connect with their prospects.
  • Similarweb Sales Intelligence helps sales teams sell smarter.
  • Similarweb Sales Intelligence is based on Similarwebs digital intelligence platform, which provides data and insights on everything from website traffic to audience engagement to search and referral data.

Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition

Retrieved on: 
Wednesday, December 8, 2021
Heart failure, ICI, Dell Technologies, Quality of life, Patient, Industry, Partnership, CHF, E&T, TEL, Engineering & Technology, Cerebral edema, Clothing, Association of British HealthTech Industries, FDA, Conditional sentence, Solution, AI, First Place, Pharmaceutical industry, Medical device

TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Donisi Health (Donisi) prevailed in this year's ICI Innovation Competition – the premier international conference for innovations in cardiovascular intervention. Competing against startups from all over the world in front of a panel of twenty industry expert judges, Donisi took home First Place honors and a $200,000 award for their innovative solution to enable in-home monitoring for key health bio-markers for patients with Congestive Heart Failure (CHF) and other chronic diseases.

Key Points: 
  • Donisi has the only clinically validated, contact-free technology that can detect signs of pulmonary congestion remotely, supporting the continuum of care for remote patient monitoring and hospital-at-home services.
  • Based upon FDA-cleared technology and backed by 11 granted patents, Donisi's AI-based system detects and analyzes multiple health bio-indicators simultaneously - without the need to remove clothing or connect the patient to wires or patches - delivering clinically meaningful insights and notifications of changes in key health indicators.
  • "We are honored to be recognized by this prestigious institution, and are grateful to the ICI team for highlighting our breakthrough technology's potential to meaningfully improve cardiovascular health," said Donisi's CEO Yair Brosh.
  • "This doesn't need to be the case," said Donisi's new Chief Medical Officer, Dr. Shaddy Hassan.

Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition

Retrieved on: 
Wednesday, December 8, 2021
Heart failure, ICI, Dell Technologies, Quality of life, Patient, Industry, Partnership, CHF, E&T, TEL, Engineering & Technology, Cerebral edema, Clothing, Association of British HealthTech Industries, FDA, Conditional sentence, Solution, AI, First Place, Pharmaceutical industry, Medical device

Donisi has the only clinically validated, contact-free technology that can detect signs of pulmonary congestion remotely, supporting the continuum of care for remote patient monitoring and hospital-at-home services.

Key Points: 
  • Donisi has the only clinically validated, contact-free technology that can detect signs of pulmonary congestion remotely, supporting the continuum of care for remote patient monitoring and hospital-at-home services.
  • Based upon FDA-cleared technology and backed by 11 granted patents, Donisi's AI-based system detects and analyzes multiple health bio-indicators simultaneously - without the need to remove clothing or connect the patient to wires or patches - delivering clinically meaningful insights and notifications of changes in key health indicators.
  • "We are honored to be recognized by this prestigious institution, and are grateful to the ICI team for highlighting our breakthrough technology's potential to meaningfully improve cardiovascular health," said Donisi's CEO Yair Brosh.
  • "This doesn't need to be the case," said Donisi's new Chief Medical Officer, Dr. Shaddy Hassan.

Panaxia and Neuraxpharm - the first in Europe to sell medical cannabis extracts for vaporization

Retrieved on: 
Wednesday, December 8, 2021
Central nervous system, Physician, Pharmacy, Database, Smoking, McNeil Consumer Healthcare, Publication, Prescription, Growth, Smoke, Patient, CEO, Inhalation, ANSM, Method, Partnership, Permira, TASE, LL, TEL, EU, CNS, Absorption, Probiotic, Marketing, Doctor of Philosophy, Chlorophyll, Australian Pesticides and Veterinary Medicines Authority, Pharmaceutical industry, Drug, Generic drug, Tourism

Thus, both companies became the first and only companies in the world to market medical cannabis extracts which may be used for vaporization in Europe.

Key Points: 
  • Thus, both companies became the first and only companies in the world to market medical cannabis extracts which may be used for vaporization in Europe.
  • At the same time, we will keep on expanding our business all over Europe, registering our products in appropriate regulatory routes".
  • Dr. Jrg-Thomas Dierks, CEO of Neuraxpharm: "With the first sales of medical cannabis extracts which may be used for vaporization in Germany, we have reached another milestone in our successful partnership with Panaxia.
  • Above all, I am delighted that we can now offer our patients in Germany even more tailored treatment options with medical cannabis."

Oramed Pharmaceuticals Appoints Chief Legal Officer

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Forward-looking statement, Company, Caspi, General counsel, Research, Knowledge, Biotechnology, Technology, Semiconductor Manufacturing International Corporation, Bar-Ilan University, Growth, Security (finance), Board of directors, Pressure, Method, Diabetes, POD, Board, TASE, Goldfarb, Norwegian Defence Security Department, Legislation, Nethaneel, Goldfarb Seligman & Co., Nasdaq, Management, Pharmaceutical industry

NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP)(TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022.

Key Points: 
  • NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP)(TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022.
  • "We are very pleased to welcome Netanel Derovan as Oramed's Chief Legal Officer.
  • Netanel's business-minded approach, legal acumenand strong operational skills will be instrumental to Oramed's ongoing progress and success and will further strengthen our executive team," stated Oramed Chief Executive Officer, Nadav Kidron.
  • Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.

Lutris Pharma Expands Intellectual Property Portfolio Surrounding its Novel B-Raf inhibitors Including Lead Asset LUT014

Retrieved on: 
Wednesday, December 8, 2021
Patent Prosecution Highway, Patent, Population, Toxicity, Technology, Radiation, Quality of life, PI3K, Skin, Patient, Breast cancer, James A. Schlipmann Melanoma Cancer Foundation, Cancer, TEL, Growth factor, RD, Mitogen-activated protein kinase, Intellectual property, Clinical trial, EGFR, Compliance, Cell, Pharmaceutical industry

TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that it has expanded the intellectual property (IP) surrounding its novel B-Raf inhibitors, including lead compound LUT014, a topically applied, novel B-Raf inhibitor for the treatment of cutaneous reactions caused by treatment with epidermal growth factor receptor (EGFR) inhibitors and/or PI3K inhibitors and treatment of radiation dermatitis (RD) caused by radiation therapy, in both the U.S. and internationally. Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.

Key Points: 
  • Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.
  • Additional non-U.S. applications have been accepted for expedited examination based on the allowed U.S. applications under the Patent Prosecution Highway program.
  • Lutris also has additional provisional patents for dosing and novel indications.
  • Additional information on the patent portfolio can be found on "Intellectual Property" section of the Lutris website at: www.lutris-pharma.com/intellectual-property .

Lutris Pharma Expands Intellectual Property Portfolio Surrounding its Novel B-Raf inhibitors Including Lead Asset LUT014

Retrieved on: 
Wednesday, December 8, 2021
Patent Prosecution Highway, Patent, Population, Toxicity, Technology, Radiation, Quality of life, PI3K, Skin, Patient, Breast cancer, James A. Schlipmann Melanoma Cancer Foundation, Cancer, TEL, Growth factor, RD, Mitogen-activated protein kinase, Intellectual property, Clinical trial, EGFR, Compliance, Cell, Pharmaceutical industry

TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that it has expanded the intellectual property (IP) surrounding its novel B-Raf inhibitors, including lead compound LUT014, a topically applied, novel B-Raf inhibitor for the treatment of cutaneous reactions caused by treatment with epidermal growth factor receptor (EGFR) inhibitors and/or PI3K inhibitors and treatment of radiation dermatitis (RD) caused by radiation therapy, in both the U.S. and internationally. Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.

Key Points: 
  • Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.
  • Additional non-U.S. applications have been accepted for expedited examination based on the allowed U.S. applications under the Patent Prosecution Highway program.
  • Lutris also has additional provisional patents for dosing and novel indications.
  • Additional information on the patent portfolio can be found on "Intellectual Property" section of the Lutris website at: www.lutris-pharma.com/intellectual-property .

Rapyd Acquires Hong Kong-Based Neat to Expand Small and Medium Business Trade Capabilities across Asia and Globally

Retrieved on: 
Wednesday, December 8, 2021
Twitter, Visa, Stripe, CHATS, SME, API, Growth, FX, Blog, General Catalyst, Super Mario, FPS, Freedom, Science and technology in Asia, CEO, Asia, Accounting, APAC, LinkedIn, SWIFT, Acquisition, Bank, Online shopping

HONG KONG and LONDON, Dec. 8, 2021 /PRNewswire/ -- Rapyd, a global Fintech-as-a-Service company has agreed to acquire Hong Kong-based Neat, a cross-border trade enabling platform for SMBs and startups. Neat provides full company incorporation, business accounts, global payment collection and disbursements, as well as credit card-based capital expansion services. Terms of the deal were not disclosed, and it is subject to regulatory approval.

Key Points: 
  • Neat provides full company incorporation, business accounts, global payment collection and disbursements, as well as credit card-based capital expansion services.
  • Its easy-to-use API-based platform simplifies complex cross-border payments processes which are critical for businesses looking to engage in global trade.
  • Neat's services, capabilities, and licenses will be integrated into Rapyd's platform providing an easy-to-use online global trade solution optimized for SMBs, entrepreneurs, and growing young companies.
  • Neat makes the world of international trade more accessible to entrepreneurs, SMEs and ambitious young companies from across the globe.